Ever Supreme Bio Technology Co FCF/Dettes

Que fait Ever Supreme Bio Technology Co ? Ever Supreme Bio Technology Co Ltd is a biotechnology company based in Taichung, Taiwan, operating within the healthcare sector. The company has 8 employees and went public on October 26, 2018. It focuses on the research, development, and sale of stem cell products. The company's website is https://www.ever-supreme.com.tw/. Ever Supreme Bio Technology Co Ltd is engaged in the development of stem cell-based therapies, with specific products including ADCV01, a dendritic cell tumor vaccine currently in Phase II clinical trials in Taiwan. The company also develops UMSC01, a human allogeneic umbilical cord stem cell product intended for the treatment of myocardial infarction. UMSC01 is approved for Phase I clinical trials by the U.S. Food and Drug Administration (FDA) and is undergoing regulatory processes in Taiwan. Additionally, the company is involved in the development of stem cell treatments for acute ischemic stroke, with clinical Phase I trials pending in the United States. The company has plans to expand its product portfolio to include mesenchymal stem cells for multiple sclerosis treatment. Ever Supreme Bio Technology Co Ltd is listed on the Taiwan Stock Exchange under ticker 6712.TWO with ISIN TW0006712003. The company's operations are centered around innovative biotechnology solutions aimed at addressing critical healthcare needs. Ever Supreme Bio Technology Co est l'une des entreprises les plus populaires sur Eulerpool.